Literature DB >> 17562498

Inflammation in cystic fibrosis--when and why? Friend or foe?

Caroline Elston1, Duncan Geddes.   

Abstract

Pulmonary infection and an excessive neutrophil-driven inflammatory response are responsible for most of the morbidity and mortality associated with cystic fibrosis. Although inflammation is first and foremost a protective response to injury or infection it has the potential to cause considerable harm when it is excessive. Whereas most published reports emphasize the damaging effects of the chronic inflammatory response in cystic fibrosis, the beneficial effects are more difficult to quantify. Low levels of inflammation may assist in clearing infection, particularly early in the disease process, and surges of acute inflammation may be beneficial during exacerbations. Anti-inflammatory therapies are used to modify the inflammatory response but there is clearly a need to preserve the protective aspects of the inflammatory response because host defense and a fine balance exist between benefit and harm. The underlying processes involved in the inflammatory response are reviewed along with current and future anti-inflammatory therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562498     DOI: 10.1055/s-2007-981649

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  5 in total

1.  CFTR inhibition provokes an inflammatory response associated with an imbalance of the annexin A1 pathway.

Authors:  Jesmond Dalli; Guglielmo Rosignoli; Richard P G Hayhoe; Aleksander Edelman; Mauro Perretti
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

2.  Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs.

Authors:  Stefanos Voglis; Kieran Quinn; Elizabeth Tullis; Mingyao Liu; Melanie Henriques; Celia Zubrinich; Oscar Peñuelas; Holman Chan; Frances Silverman; Vera Cherepanov; Neil Orzech; Aye Aye Khine; André Cantin; Arthur S Slutsky; Gregory P Downey; Haibo Zhang
Journal:  Am J Respir Crit Care Med       Date:  2009-04-30       Impact factor: 21.405

3.  Neutrophils in cystic fibrosis display a distinct gene expression pattern.

Authors:  Minou Adib-Conquy; Thierry Pedron; Anne-France Petit-Bertron; Olivier Tabary; Harriet Corvol; Jacky Jacquot; Annick Clément; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

4.  Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.

Authors:  David A Stoltz; David K Meyerholz; Alejandro A Pezzulo; Shyam Ramachandran; Mark P Rogan; Greg J Davis; Robert A Hanfland; Chris Wohlford-Lenane; Cassie L Dohrn; Jennifer A Bartlett; George A Nelson; Eugene H Chang; Peter J Taft; Paula S Ludwig; Mira Estin; Emma E Hornick; Janice L Launspach; Melissa Samuel; Tatiana Rokhlina; Philip H Karp; Lynda S Ostedgaard; Aliye Uc; Timothy D Starner; Alexander R Horswill; Kim A Brogden; Randall S Prather; Sandra S Richter; Joel Shilyansky; Paul B McCray; Joseph Zabner; Michael J Welsh
Journal:  Sci Transl Med       Date:  2010-04-28       Impact factor: 17.956

5.  Understanding resolvin signaling pathways to improve oral health.

Authors:  David Keinan; Noel J Leigh; Joel W Nelson; Laura De Oleo; Olga J Baker
Journal:  Int J Mol Sci       Date:  2013-03-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.